MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Up 0.8% – What’s Next?

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA)’s share price shot up 0.8% during mid-day trading on Monday . The company traded as high as $1.34 and last traded at $1.33. 136,416 shares were traded during mid-day trading, a decline of 84% from the average session volume of 870,748 shares. The stock had previously closed at $1.32.

Analysts Set New Price Targets

Separately, Wall Street Zen cut shares of MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 5th.

MIRA Pharmaceuticals Price Performance

The company has a fifty day moving average of $1.46 and a 200 day moving average of $1.28. The firm has a market capitalization of $25.36 million, a P/E ratio of -2.71 and a beta of 1.75.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its earnings results on Thursday, August 14th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. On average, sell-side analysts forecast that MIRA Pharmaceuticals, Inc. will post -0.6 EPS for the current year.

Hedge Funds Weigh In On MIRA Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of MIRA. XTX Topco Ltd acquired a new position in shares of MIRA Pharmaceuticals during the second quarter worth approximately $26,000. Creative Planning purchased a new stake in MIRA Pharmaceuticals in the 2nd quarter valued at $27,000. Two Sigma Investments LP purchased a new stake in MIRA Pharmaceuticals in the 4th quarter valued at $28,000. Northern Trust Corp grew its stake in MIRA Pharmaceuticals by 50.9% in the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock valued at $35,000 after purchasing an additional 10,238 shares during the period. Finally, International Assets Investment Management LLC bought a new position in MIRA Pharmaceuticals in the 2nd quarter valued at $42,000. 35.16% of the stock is currently owned by institutional investors.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.